APA (7th ed.) Citation

RS, F., BY, R., CH, H., D, L., AM, B., C, C., . . . E, G. (2025). Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): A randomised, open-label, phase 1b-2, study. The Lancet. Oncology, 26(2), 214. https://doi.org/10.1016/S1470-2045(24)00679-X

Chicago Style (17th ed.) Citation

RS, Finn, et al. "Tiragolumab in Combination with Atezolizumab and Bevacizumab in Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma (MORPHEUS-Liver): A Randomised, Open-label, Phase 1b-2, Study." The Lancet. Oncology 26, no. 2 (2025): 214. https://doi.org/10.1016/S1470-2045(24)00679-X.

MLA (9th ed.) Citation

RS, Finn, et al. "Tiragolumab in Combination with Atezolizumab and Bevacizumab in Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma (MORPHEUS-Liver): A Randomised, Open-label, Phase 1b-2, Study." The Lancet. Oncology, vol. 26, no. 2, 2025, p. 214, https://doi.org/10.1016/S1470-2045(24)00679-X.